We came across a bullish thesis on Kenvue Inc. on The Value Road’s Substack. In this article, we will summarize the bulls’ thesis on KVUE which was published before KVUE's acquisition announcement. Kenvue Inc.'s share was trading at $17.35 as of November 28th. KVUE’s trailing and forward P/E were 23.13 and 15.77 respectively according to Yahoo Finance. 30 Funniest Science Jokes, Puns, and Humor Quotes Ever pikselstock/Shutterstock.com Kenvue Inc. operates as a consumer health company in the United State ...

Core Insights - The company has recently announced divestitures, specifically regarding Kepware and ThingWorx, which have raised questions about the strategic rationale behind these decisions [1] Group 1: Divestitures - The divestitures of Kepware and ThingWorx were influenced by a shift in the direction of these businesses, which has diverged from the company's core focus [1] - There was significant effort invested in these deals in the past, indicating that the decision to divest is strategic rather than impulsive [1]

Core Insights - Medtronic Plc reported second-quarter earnings and announced key board appointments following Elliott Investment Management becoming the largest shareholder [1] - The company introduced a new Growth Committee to oversee strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business [1] Financial Performance - Medtronic's first-quarter 2026 sales reached $8.58 billion, exceeding the consensus estimate of $8.38 billion, representing an 8.4% year-over-year increase with organic growth of 4.8% [2] - Adjusted earnings per share were $1.26, surpassing expectations of $1.23 [2] Sales Guidance - The company raised its sales guidance for fiscal 2026 from a range of $35.15 billion to $35.25 billion to a new range of $35.72 billion to $35.82 billion, compared to the consensus of $35.32 billion [3] Analyst Reactions - Needham's analyst Mike Matson believes Medtronic is in the early stages of a strong product cycle and expects Elliott's involvement to enhance shareholder value, but maintains a Hold rating until organic growth shows meaningful acceleration beyond 5% [4] - Matson raised fiscal 2026 and 2027 revenue estimates to $35.81 billion from $35.29 billion and to $37.69 billion from $36.96 billion, respectively [5] - Bernstein maintains an Outperform rating on Medtronic, raising the price forecast from $97 to $98, while Baird maintains a Neutral rating, increasing the price forecast from $94 to $96 [6] Stock Performance - Medtronic's stock increased by 4.07%, reaching $93.56 at the last check on Wednesday [6]